Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Intangibles (2020 - 2025)

Moleculin Biotech's Intangibles history spans 6 years, with the latest figure at $11.1 million for Q4 2025.

  • Quarterly results put Intangibles at $11.1 million for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $11.1 million (changed 0.0% YoY), and the annual figure for FY2025 was $11.1 million, changed 0.0%.
  • Intangibles for Q4 2025 was $11.1 million at Moleculin Biotech, roughly flat from $11.1 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $11.1 million in Q4 2021 to a low of $11.1 million in Q4 2021.
  • The 5-year median for Intangibles is $11.1 million (2021), against an average of $11.1 million.
  • Peak annual rise in Intangibles hit 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
  • Year by year, Intangibles stood at $11.1 million in 2021, then changed by 0.0% to $11.1 million in 2022, then changed by 0.0% to $11.1 million in 2023, then changed by 0.0% to $11.1 million in 2024, then changed by 0.0% to $11.1 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $11.1 million, $11.1 million, and $11.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.